Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Silver One Resources Inc. stock logo
SVE
Silver One Resources
C$0.28
-3.4%
C$0.24
C$0.17
C$0.39
C$79.90M1.57100,350 shs117,384 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$3.70
+4.5%
$2.82
$1.87
$11.40
$323.15M-0.181.51 million shs843,884 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Silver One Resources Inc. stock logo
SVE
Silver One Resources
+9.43%+9.43%+9.43%+11.54%+7.41%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
+0.85%+14.19%+17.61%+1.43%-48.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Silver One Resources Inc. stock logo
SVE
Silver One Resources
N/AN/AN/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.9769 of 5 stars
3.31.00.04.13.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Silver One Resources Inc. stock logo
SVE
Silver One Resources
0.00
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63322.30% Upside

Current Analyst Ratings Breakdown

Latest PIRI, TERN, SVE, and DGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
3/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Silver One Resources Inc. stock logo
SVE
Silver One Resources
N/AN/AC$0.02 per share12.27C$0.15 per shareN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Silver One Resources Inc. stock logo
SVE
Silver One Resources
-C$2.80M-C$0.01N/AN/AN/A-6.93%-3.30%N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)

Latest PIRI, TERN, SVE, and DGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
3/20/2025Q4 2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Silver One Resources Inc. stock logo
SVE
Silver One Resources
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Silver One Resources Inc. stock logo
SVE
Silver One Resources
N/A
57.92
21.35
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
32.99
32.99

Institutional Ownership

CompanyInstitutional Ownership
Silver One Resources Inc. stock logo
SVE
Silver One Resources
8.09%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Silver One Resources Inc. stock logo
SVE
Silver One Resources
16.60%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Silver One Resources Inc. stock logo
SVE
Silver One Resources
N/A285.36 millionN/ANot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million72.11 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Silver One Resources stock logo

Silver One Resources CVE:SVE

C$0.28 -0.01 (-3.45%)
As of 03:59 PM Eastern

Silver One Resources Inc., together with its subsidiary, engages in the acquisition, exploration, and development of mineral properties in the United States. The company explores for silver deposits. Its flagship project, the Candelaria Silver Mine project, located in central west Nevada; and holds 100% interest in Cherokee project located in Nevada, as well as in the Phoenix silver property located near Globe, Arizona. The company was formerly known as BRS Ventures Ltd. and changed its name to Silver One Resources Inc. in September 2016. Silver One Resources Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$3.70 +0.16 (+4.52%)
Closing price 04:00 PM Eastern
Extended Trading
$3.74 +0.03 (+0.95%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.